3759
document
Reduction of oral mucositis by filgrastim ( r-metHuG-CSF ) in patients receiving chemotherapy . Mucositis , the inflammation and necrosis of mucosal membranes , is a serious and debilitating consequence of many cancer therapies . We were interested in the potential role of filgrastim ( recombinant methionyl human granulocyte colony-stimulating factor , r-metHuG-CSF ) in the reduction of mucositis . Patients with newly diagnosed small-cell lung cancer ( SCLC ) were treated with CAE chemotherapy ( cyclophosphamide , doxorubicin , and etoposide ) and placebo or filgrastim . If patients had an episode of febrile neutropenia , they received unblinded filgrastim in subsequent CAE cycles . Oral mucositis was considered to have occurred if a patient reported any clinical sign or symptom of oral mucositis with or without oral candidiasis . Oral mucositis was analyzed using the unadjusted chi-square test , and time to first episode of mucositis was analyzed using the stratified log-rank test as well as the Cox proportional hazards regression model . During cycle 1 , placebo-treated patients had more episodes of mucositis ( 47 % ) compared with those patients randomized to filgrastim ( 28 % ) . Across all cycles of treatment , 70 % of placebo-treated patients experienced mucositis , compared with 53 % of patients randomized to filgrastim . A significant reduction in the incidence of chemotherapy-related oral mucositis occurred across multiple cycles of treatment in patients treated with filgrastim .
3760
Intervention_Pharmacological
filgrastim
3761
Intervention_Pharmacological
r-metHuG-CSF
3762
Intervention_Pharmacological
chemotherapy
3763
Intervention_Pharmacological
filgrastim
3764
Intervention_Pharmacological
recombinant methionyl human granulocyte colony-stimulating factor
3765
Intervention_Pharmacological
r-metHuG-CSF
3766
Intervention_Pharmacological
CAE chemotherapy
3767
Intervention_Pharmacological
cyclophosphamide
3768
Intervention_Pharmacological
doxorubicin
3769
Intervention_Pharmacological
etoposide
3770
Intervention_Control
placebo
3771
Outcome_Physical
Reduction of oral mucositis
3772
Outcome_Physical
Mucositis
3773
Outcome_Physical
reduction of mucositis
3774
Outcome_Physical
Oral mucositis
3775
Outcome_Physical
symptom of oral mucositis with or without oral candidiasis
3776
Outcome_Physical
Oral mucositis
3777
Outcome_Physical
time to first episode of mucositis
3778
Outcome_Physical
mucositis
3779
Outcome_Physical
mucositis
3780
Outcome_Physical
oral mucositis
3781
Participant_Condition
patients receiving chemotherapy
3782
Participant_Condition
newly diagnosed small-cell lung cancer ( SCLC )